ANI Prescribed drugs’ ANIP uncommon illness franchise spearheaded its progress in 2025. This strong progress was fueled by the robust efficiency of its ACTH-based injection Cortrophin Gel.
Cortrophin Gel gross sales jumped 70% 12 months over 12 months to $236 million within the first 9 months of 2025, witnessing broad-based progress throughout all focused specialties, supported by an expanded gross sales power in neurology, rheumatology, and nephrology, in addition to synergies from the built-in ophthalmology gross sales workforce.
Throughout the third quarter, the corporate reported continued progress in prescriptions for the prefilled syringe, which represented roughly 70% of newly initiated instances. Prescriptions for acute gouty arthritis flares — a sign during which Cortrophin Gel is the one accredited ACTH-based remedy — continued to be a key progress contributor, accounting for greater than 15% of general Cortrophin Gel utilization.
A section IV examine evaluating Cortrophin Gel in acute gouty arthritis flares is ongoing.
ANIP expects this momentum to proceed in 2026 as properly. ANIP expects its uncommon illness enterprise to characterize half of its whole internet revenues in 2025. For full-year 2025, Cortrophin Gel gross sales are projected to succeed in $347-$352 million, representing progress of 75-78% 12 months over 12 months.
The robust efficiency of the uncommon illness franchise helps offset weaker-than-expected contributions from ANI’s just lately acquired ophthalmology merchandise, Iluvien and Yutiq, which had been added via the September 2024 acquisition of Alimera Sciences.
ANIP’s Competitors within the House
ANI Prescribed drugs’ ophthalmology merchandise, Iluvien and Yutiq, face competitors from a number of pharma bigwigs, like AbbVie ABBV and Regeneron REGN.
AbbVie is a key rival, with Ozurdex competing immediately with Iluvien in diabetic macular edema (DME) and with Yutiq in non-infectious uveitis of the posterior section (NIU-PS).
Regeneron can be a formidable competitor, led by its trade high ophthalmology franchise comprising Eylea, probably the most extensively used therapies in DME.
The prime competitor to Cortrophin Gel is Acthar Gel, which is marketed by Keenova Therapeutics (previously Mallinckrodt Prescribed drugs). Like ANIP, Keenova just lately raised the gross sales outlook for Acthar Gel, now anticipating full-year 2025 gross sales progress of 30-35%, up from the prior 20-30% vary.
ANIP’s Worth Efficiency, Valuation and Estimates
ANIP’s shares have gained 42.3% in a 12 months in contrast with the trade’s progress of 17.6%.
Picture Supply: Zacks Funding Analysis
From a valuation standpoint, ANIP is buying and selling at a premium to the trade. Going by the worth/gross sales (P/S) ratio, the inventory at the moment trades at 2.04X trailing 12-month gross sales worth, greater than 1.92x for the trade.
Picture Supply: Zacks Funding Analysis
EPS estimates for 2025 and 2026 have elevated during the last 60 days.
Picture Supply: Zacks Funding Analysis
ANI Prescribed drugs at the moment sports activities a Zacks Rank #1 (Robust Purchase). You possibly can see the entire checklist of at this time’s Zacks #1 Rank shares right here.
Quantum Computing Shares Set To Soar
Synthetic intelligence has already reshaped the funding panorama, and its convergence with quantum computing may result in probably the most important wealth-building alternatives of our time.
Immediately, you could have an opportunity to place your portfolio on the forefront of this technological revolution. In our pressing particular report, Past AI: The Quantum Leap in Computing Energy, you may uncover the little-known shares we consider will win the quantum computing race and ship huge positive factors to early traders.
Regeneron Prescribed drugs, Inc. (REGN) : Free Inventory Evaluation Report
AbbVie Inc. (ABBV) : Free Inventory Evaluation Report
ANI Prescribed drugs, Inc. (ANIP) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
